Life Sciences and Healthcare

Roche’s Hemlibra: Market expansion approved, but safety an initial concern?

The annual industry forecast and analysis report Drugs to Watch from Clarivate Analytics was published in March 2018, detailing the pharma industry’s expected blockbuster launches for 2018. The report was led by Roche/Chugai’s hemophilia drug Hemlibra (emicizumab), for which analysts had very big expectations, and consensus forecasts stood at $4.002 billion for 2022 at the […]

Global issues stir debate at the 2018 MedTech Conference

News from the global stage resonated throughout the MedTech Conference as the industry gathered in Philadelphia for AdvaMed’s annual meeting.  Among the liveliest sessions were those focused on the future of the clinical trials landscape in the U.K. as a result of Brexit, the impact of trade wars on the industry, and Jeff Shuren, the […]

Predictive analytics yield smarter pharma portfolio decisions

Collecting competitive data isn’t the problem; most biopharma companies are drowning in it. But making sense of the data, using it to predict likely shifts in the competitive landscape and drive decisions can be a challenge. While forecasting drug timelines and success rates are critical to inform investment and R&D decisions, the standard approach has […]

Erleada gains first-mover advantage in CRPC

The 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics, predicted approval and market entry of Johnson & Johnson’s Erleada (apalutamide), the first FDA-approved treatment for non-metastatic castration-resistant prostate cancer (CRPC).1,2 This approval came two months ahead of its April 2018 PDUFA date and only four months after its […]

CV Risk: Vascepa Doesn’t just REDUCE-IT, Vascepa Slashes it

I must admit it, I am surprised by the scale of the risk reduction that Amarin Corporation’s Vascepa (icosapent ethyl) has delivered in the REDUCE-IT cardiovascular outcomes trial (CVOT).   REDUCEd-IT and more In this trial of more than 8,000 statin-treated primary and secondary CV prevention patients with moderately raised triglyceride (TGs) levels, Vascepa was […]

How Common is In-Office Dispensing of Oral Prostate Cancer Drugs?

The growing trend of physicians dispensing of oral oncolytics directly to patients disrupts the U.S. reimbursement system’s traditional reliance upon insurers’ specialty pharmacies. Key finding:  Three quarters of oncologists and urologists surveyed by DRG reported that their practices have the capability to dispense oral prostate cancer drugs through their practice’s licensed pharmacy (most common) or […]

Generics companies, responding to tough times, steer towards higher-risk portfolio strategies

These are tough times financially and strategically for many generics companies, particularly in the U.S., the world’s largest pharmaceutical market. Manufacturers are experiencing falling net prices driven by customer consolidation and increasing competition, coupled with a lack of operational flexibility and a landscape of new product opportunities significantly different from those of the past. Additionally, […]

Forecasting the Market Impact of Generic Xeljanz

What are the most important factors to consider when forecasting the launch of generic Xeljanz? Pfizer’s Xeljanz was the first Janus kinase (Jak) inhibitor to launch in a major market, after its approval as a treatment for rheumatoid arthritis (RA) in the United States in 2012. It is now approved in all major markets for […]

Key Q2 partnerships driving biopharma

Introduction During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and $35.6 billion in the first quarter and 1,104 and $13.6 […]

How Disney is Disrupting Orlando Healthcare

American employers experimenting with direct provider contracts usually do it on a small scale, but Walt Disney World Resorts in Orlando is fully committing with provider HMOs that insure most of the company’s Orlando workforce. With a possible 70,000 Orlandoans receiving care solely from the provider networks of Orlando’s two largest integrated delivery networks, the […]